I Am Bhojpuriya

Category: Health

  • Indian Pharmaceutical Company conducts Clinical Analysis for the Supplement to battle against Post COVID-19 difficulties

    ImmunoSEB + ProbioSEB CSC3 for post-resolution of mild to moderate COVID-19 patients

     

    Mumbai, Maharashtra [India], June 21: According to recent stats, 2.77 crores of COVID-19 sufferers were recovered from 2.88 crores cases in India. All corporate offices and businesses want to operate outdoors but worry much about the Post Covid difficulties and resolutions. While companies were involved in launching products and promoting claims that it fights the Coronavirus, researchers ran clinical tests to confirm how consuming immunity supplements resolve mild to moderate COVID-19 patients.

    Dr. Neha Shah, Dr. Rohit Parate, and Dr. Abhay Vispute published their findings on a new COVID-19 clinical trial in the Medical Journal of Advances in Clinical Toxicology. A randomized, open-label, 2 Arm, prospective study was investigated for the safety and efficacy of the health supplements. Fortunately, ImmunoSEB + ProbioSEB CSC3 as supplemental therapy was confirmed to be beneficial in mild to moderate COVID-19 patients and showed overall clinical improvement in WHO 7-point ordinal scale.

    They investigated to evaluate the effect on the primary endpoint of the experimental regimen through pairwise comparisons of the testing regimen ImmunoSEB + ProbioSEB CSC3 with a standard-of-care control arm and under a sequential design. The clinical trials were carried out on 60 patients in two centers, SRV Hospital, Mumbai and Chirayu Medical College, and Hospital, Bhopal.

    As the World Health Organization rightly defines probiotics as “live microorganisms that administer adequate amounts confer a health benefit on the host.” ImmunoSEB + ProbioSEB CSC3 are different as they increase immunity and improves digestion, aiding in reducing fatigue. In addition, it’s a nutraceuticals product, the only product with clinical trials as a supplement to fight against Covid-19.

    Recent clinical studies indicate that this Supplement supports the recovery of covid patients. The length of time to experience the benefits of the Supplement varies by individual. Some people notice a difference within days. For others, it’s a week or ten days. For long-term benefits, it’s essential to take the immunity bundle consistently over several months. Regular, consistent use of the Supplement will provide the best results. However, missed doses of the Supplement do not cause any harm. Consume the following amount as per your daily regime.

    According to Management of Post COVID-19 Fatigue using Systemic Enzymes and Probiotics- Case Series covered by the Medical Journal of Clinical Trials and Case Studies; “The present cases support the use of a 14 days supplementation of a combination of ImmunoSEB + ProbioSEB CSC3 to improve COVID-19 induced fatigue in patients post-resolution of mild to moderate COVID-19 disease. However, there is a need for large-scale, placebo-controlled prospective studies to evaluate this effect further.”

    The team of doctors and researchers includes Dr. Neha Shah, Dr. Rohit Parate, Dr. Abhay Vispute.

    Dr. Rohit Parate, MD Medicine, Churayu Medical College, and Hospital, observes patients with a Generalised Weakness, Dry Cough, Body Ache, Loss of Appetite, and Constipation for post-covid symptoms. Whereas Dr. Kuldeep Kataria, MD Medicine, Swasthya Hospital, follows over 75% of the patients with Sleep disturbance, Severe Body Ache, Abdominal Cramps, and Heaviness in the chest.

    Dr. Sanket Ramesh Mundada, MBBS, DPM, Namrata Neureoschyetric Hospital, Shrirampur conveys, “Post Covid patient with anxiety symptoms, disturbed sleep, depression. Withholding due to the death of the loved ones in Covid, psychosis has increased in OPDs. We have seen cases of fear of getting infected or fear of spreading the infection to family members increasing, causing many palpitations, trembling, sweating in patients. Counseling and appropriate medication help along with immunity booster help maintain the mental and physical health of the patient.”

    “Throughout this pandemic situation, we tried hard to fix this unsolvable puzzle of saving lives post-covid with natural solutions that can help people who are grieving. Enzymes and probiotics are robust mechanisms for stamina and vitality, and the medicine and investigation confirm it.” conveys Dr. Neha Shah, Ph.D. Program Coordinator, Navigate a&Swog, VA Long Beach Healthcare, California.

    Mr. MukundKabra, Director, Advanced Enzymes, states, “the reason is evident for post-COVID-19 and should heal as any prevalent disease. Advanced Enzymes remedied Americans for over 30 years. Aiding to enhance immunity amongst Indians was our prime focus in this pandemic. Hence, the research-backed Immunity Bundle was made available online. Doctors should address post-COVID immunity immediately because it is affecting a lot of people’s quality of life.”

    Dr. Abhijit K Rathi, the Principal Scientist from AET, “ImmunoSEB and Biome Ultra were tested in a few hospitals, clinics, random patients and discovered their feedback. People’s difficulties before the testing were traumatizing. However, after consuming ImmunoSEB and Biome Ultra for some days, the same target group conveyed their curing stories and enhanced immunity evidence.”

  • HealWell24 looking to bridge gaps in healthcare sector in India with DocsCampus.com

    Mumbai (Maharashtra) [India], June 17: COVID-19 pandemic revealed the gaps in the existing healthcare structure and showed that the Indian healthcare system is too weak.

    With a lower doctor-patient ratio (1:1000), issues in last-mile healthcare delivery, and lack of qualified doctors in rural & semi-urban areas, the Indian HealthCare system needs a revolution.

    There is no effective, trusted single window for healthcare delivery to everyone and no proven way for professionals to find, consult, transact with each other online.

    Providing a solution to all these issues, JK Singha, Rk Ningthem, Nilesh Bhanushali, and Chittaranjan Mishra started HealWell24.

    In Jan 2021, Anil Va Verma, a top executive in a major beauty care startup, joined HealWell24 as Chief Investment Officer.

    The idea behind the next chapter of HealWell24 emanates from a deep and personal experience of the team.

    It is to solve for the current asymmetry of Indian Healthcare (of information & access), no booking engine (such as HealWell24.com or Practo.com) will ever be sufficient at a scale, which has become obvious to the entire world during the two waves of the Covid-19 pandemic.

    It would need a simple engine and a user-managed network of Doctors and Patients, owned and moderated with the community at its center stage.

    DocsCampus.com, the upcoming product of HealWell24, plans to solve exactly this in a simple to use and effective platform for the next generation, stated the founder.

    The Healthtech startup currently provides an easy-to-use web and mobile platform where members can connect with India’s top doctors – 24/7, 365 days a year.

    Speaking about the platform, JK Singha says, “HealWell24, the current product, already empowers individuals with remote screening, where patients can connect with their dedicated doctors anytime, from anywhere, and engage in live video sessions. We also provide additional support, like doctor home visits, home lab tests, or medicine delivery, to our customers- all of which are fulfilled on the same day by our team. But with DocsCampus, we would consider us successful when we have removed the existing asymmetry of access & information for doctors or medical students in rural/ semi-urban areas & their patients.

    Although the DocsCampus portal is not expected to be monetized in the coming quarters, till it hits an inflection point, the services of the current booking engine will be deeply integrated to ensure top quality service delivery to all the doctors on the platform and their patients.

    The company will be moving into the next phases of DocsCampus lifecycle in the coming three quarters from launch, of which I remain tightlipped but extremely excited about.”

    Operational in 35 cities, HealWell24 has 1000+ doctors, 300+ Labs, and 100+ Dentists on its platform. The startup has Apollo Spectra, Indian Oil, Hiranandani Hospital, Mahindra Lifespaces, Synechron technologies, Zeno Health as Corporate Clients, and several well-established companies in diagnostics chains & hospitals as partners.

    Till now, HealWell24 has provided essential healthcare service to thousands of Indians for conditions such as bone cancer, dental abscesses, and diabetic retinopathy.

    With over 215K consumer transacted so far, HealWell24 currently handles over 600 transactions per day.

    HealWell24 has aggressive growth plans and is looking to raise Series A in the next two months. The startup had already raised a total of $1.1Mn from Seed and Its Pre-Series A Rounds.

  • HealWell24 looking to bridge gaps in healthcare sector in India with DocsCampus.com

    Mumbai (Maharashtra) [India], June 17: COVID-19 pandemic revealed the gaps in the existing healthcare structure and showed that the Indian healthcare system is too weak.

    With a lower doctor-patient ratio (1:1000), issues in last-mile healthcare delivery, and lack of qualified doctors in rural & semi-urban areas, the Indian HealthCare system needs a revolution.

    There is no effective, trusted single window for healthcare delivery to everyone and no proven way for professionals to find, consult, transact with each other online.

    Providing a solution to all these issues, JK Singha, Rk Ningthem, Nilesh Bhanushali, and Chittaranjan Mishra started HealWell24.

    In Jan 2021, Anil Va Verma, a top executive in a major beauty care startup, joined HealWell24 as Chief Investment Officer.

    The idea behind the next chapter of HealWell24 emanates from a deep and personal experience of the team.

    It is to solve for the current asymmetry of Indian Healthcare (of information & access), no booking engine (such as HealWell24.com or Practo.com) will ever be sufficient at a scale, which has become obvious to the entire world during the two waves of the Covid-19 pandemic.

    It would need a simple engine and a user-managed network of Doctors and Patients, owned and moderated with the community at its center stage.

    DocsCampus.com, the upcoming product of HealWell24, plans to solve exactly this in a simple to use and effective platform for the next generation, stated the founder.

    The Healthtech startup currently provides an easy-to-use web and mobile platform where members can connect with India’s top doctors – 24/7, 365 days a year.

    Speaking about the platform, JK Singha says, “HealWell24, the current product, already empowers individuals with remote screening, where patients can connect with their dedicated doctors anytime, from anywhere, and engage in live video sessions. We also provide additional support, like doctor home visits, home lab tests, or medicine delivery, to our customers- all of which are fulfilled on the same day by our team. But with DocsCampus, we would consider us successful when we have removed the existing asymmetry of access & information for doctors or medical students in rural/ semi-urban areas & their patients.

    Although the DocsCampus portal is not expected to be monetized in the coming quarters, till it hits an inflection point, the services of the current booking engine will be deeply integrated to ensure top quality service delivery to all the doctors on the platform and their patients.

    The company will be moving into the next phases of DocsCampus lifecycle in the coming three quarters from launch, of which I remain tightlipped but extremely excited about.”

    Operational in 35 cities, HealWell24 has 1000+ doctors, 300+ Labs, and 100+ Dentists on its platform. The startup has Apollo Spectra, Indian Oil, Hiranandani Hospital, Mahindra Lifespaces, Synechron technologies, Zeno Health as Corporate Clients, and several well-established companies in diagnostics chains & hospitals as partners.

    Till now, HealWell24 has provided essential healthcare service to thousands of Indians for conditions such as bone cancer, dental abscesses, and diabetic retinopathy.

    With over 215K consumer transacted so far, HealWell24 currently handles over 600 transactions per day.

    HealWell24 has aggressive growth plans and is looking to raise Series A in the next two months. The startup had already raised a total of $1.1Mn from Seed and Its Pre-Series A Rounds.

  • Thermo Fisher Scientific expands its SARS-CoV-2 testing portfolio in India with a point-of-care testing platform

    The Accula System is an innovative platform that will accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care.

    Mumbai (Maharashtra) [India], June 15: Thermo Fisher Scientific today announced the introduction of the new and innovative Accula SARS-CoV-2 Test that delivers gold-standard reverse transcription-polymerase chain reaction (RT-PCR) detection of SARS-CoV-2 in a point-of-care format.

    The Accula SARS-CoV-2 Test has received Emergency Use Authorization (EUA) from the United States (U.S.) Food and Drug Administration (FDA) for the detection of SARS-CoV-2 in Clinical Laboratory Improvement Amendments (CLIA)–waived environments.

    “Since the start of the pandemic, Thermo Fisher has acted quickly to provide support to the scientists and healthcare professionals at the frontlines of combating COVID-19,” said Amit Chopra, Managing Director, India, and South Asia, Thermo Fisher Scientific. “Thermo Fisher’s new testing platform combines the accuracy of RT-PCR with the simplicity, convenience, and procedural familiarity of traditional rapid immunoassays. The Accula SARS-CoV-2 Test is a natural extension to our existing offerings and will significantly help to meet the continuing demands for rapid and reliable COVID-19 testing in India.”

    RT-PCR testing is streamlined from start to finish using a fully integrated, single-use microfluidic test cassette and the reusable, palm-sized Accula Dock. The test uses nasal swab samples and provides reliable, qualitative results in approximately 30 minutes. The Accula SARS-CoV-2 Test is enabled by proprietary PCR technology that allows for reduced absolute temperatures and reduced temperature differentials—resulting in rapid exponential amplification while reducing overall thermocycling times.

    “The rapid Accula point-of-care test will open new avenues of personal and public testing without compromising on accuracy,” added Amit. “The introduction of the test in India is a demonstration of the impact our solutions have on human health during the pandemic, and far beyond.”

    In January 2021, Thermo Fisher acquired Mesa Biotech Inc., which developed the Accula SARS-CoV-2 Test to provide accurate and faster results at the point of care.

    For more information, please visit www.thermofisher.com

    Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner, and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies, or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience, and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon.

  • Thermo Fisher Scientific expands its SARS-CoV-2 testing portfolio in India with a point-of-care testing platform

    The Accula System is an innovative platform that will accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care.

    Mumbai (Maharashtra) [India], June 15: Thermo Fisher Scientific today announced the introduction of the new and innovative Accula SARS-CoV-2 Test that delivers gold-standard reverse transcription-polymerase chain reaction (RT-PCR) detection of SARS-CoV-2 in a point-of-care format.

    The Accula SARS-CoV-2 Test has received Emergency Use Authorization (EUA) from the United States (U.S.) Food and Drug Administration (FDA) for the detection of SARS-CoV-2 in Clinical Laboratory Improvement Amendments (CLIA)–waived environments.

    “Since the start of the pandemic, Thermo Fisher has acted quickly to provide support to the scientists and healthcare professionals at the frontlines of combating COVID-19,” said Amit Chopra, Managing Director, India, and South Asia, Thermo Fisher Scientific. “Thermo Fisher’s new testing platform combines the accuracy of RT-PCR with the simplicity, convenience, and procedural familiarity of traditional rapid immunoassays. The Accula SARS-CoV-2 Test is a natural extension to our existing offerings and will significantly help to meet the continuing demands for rapid and reliable COVID-19 testing in India.”

    RT-PCR testing is streamlined from start to finish using a fully integrated, single-use microfluidic test cassette and the reusable, palm-sized Accula Dock. The test uses nasal swab samples and provides reliable, qualitative results in approximately 30 minutes. The Accula SARS-CoV-2 Test is enabled by proprietary PCR technology that allows for reduced absolute temperatures and reduced temperature differentials—resulting in rapid exponential amplification while reducing overall thermocycling times.

    “The rapid Accula point-of-care test will open new avenues of personal and public testing without compromising on accuracy,” added Amit. “The introduction of the test in India is a demonstration of the impact our solutions have on human health during the pandemic, and far beyond.”

    In January 2021, Thermo Fisher acquired Mesa Biotech Inc., which developed the Accula SARS-CoV-2 Test to provide accurate and faster results at the point of care.

    For more information, please visit www.thermofisher.com

    Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner, and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies, or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience, and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon.

  • The new app brings hope to 70,000 cancer patients seeking reliable information to navigate their treatment journey

    Pune (Maharashtra) [India], June 15: Cancer patients in India now have access to CURIA, a first-of-its-kind app developed by Swiss company OncoCoin AG, the most decentralized and equitable ecosystem of cancer information. CURIA, with a global community of over 150,000, empowers patients with individualised information on treatments, clinical trials, and experts. It provides them with the much-needed support to navigate the tough decisions throughout their treatment journey.

    According to a report by WHO, 1 in every 10 Indians will develop cancer in their lifetime. There were as many as 1.16 million new cancer cases and 784,800 cancer deaths in 2018 alone. High mortality, combined with over 500 types of cancers, has generated a need for highly relevant information more than ever before.

    CURIA empowers patients and their families with individualized information about approved therapies, clinical trials, and medical experts. Built over the OncoCoin platform, CURIA offers services such as tailored information, second opinion, and the opportunity to participate in research programmes. The timely availability of this information at patient’s fingertips helps them navigate through tough decisions throughout their treatment journey.

    Speaking of this, Amit Ananpara, Innoplexus India Co-MD, said “Globally, 70% of cancer patients feel they do not get the information they need to make informed decisions. Specifically in India, limited knowledge of ongoing clinical trials leaves a gap in research involvement, stifling new insights. CURIA has successfully bridged such gaps in Europe. We look forward to helping cancer patients in India in their journey to cure.”

    Amit Ananpara and Gunjan Bhardwaj

    The tailored options in the app seek to answer three main questions which are often at the forefront of patients’ minds when they are diagnosed with cancer: ‘What are the treatment options available to me’, ‘What clinical trials could I participate in’, and ‘Who are the experts for my cancer type’. CURIA serves as a basis for patients to understand those options for their treatment journey, and to have more engaged discussions with their doctors about what’s right for them.

    Adding further, Gunjan Bhardwaj, Founder & CEO, Innoplexus, said, “Cancer is one of the most common non-communicable diseases in India today. What exacerbates the situation further is the fact that there is a clear lack of information on the condition. We aim to bridge this gap through CURIA and enable individuals with this condition to connect with other cancer patients and share information.”

    CURIA’s popular feature “Cancer Twin”, addresses patients’ need to connect with someone who really understands what they’re going through. The algorithm matches patients with the most similar other cancer profiles. They can share experiences through a private chat, anonymously. All conversations are encrypted through blockchain, bringing in the highest level of security to protect patient’s vital health information.

    CURIA’s India launch follows successful launches in Germany, Italy, Spain, Switzerland, and France. It is available on Android and iOS platforms.

    About Curia

    CURIA is a mobile application developed by OncoCoin AG, a Swiss-based wholly-owned subsidiary of Innoplexus AG. OncoCoin, using its patented AI and blockchain technologies, structures trillions of data points from published and unpublished data. The information is tailored by parameters such as demographics, cancer type, stage, possible mutations, to generate the most relevant insights for quick decision making. The insights are fully regulated by a human team of experts. Curia was founded in June 2020 by Innoplexus AG and sits in Eschborn, Germany. The app is currently available in Germany, India, Italy, France, Spain, and Switzerland.

  • The new app brings hope to 70,000 cancer patients seeking reliable information to navigate their treatment journey

    Pune (Maharashtra) [India], June 15: Cancer patients in India now have access to CURIA, a first-of-its-kind app developed by Swiss company OncoCoin AG, the most decentralized and equitable ecosystem of cancer information. CURIA, with a global community of over 150,000, empowers patients with individualised information on treatments, clinical trials, and experts. It provides them with the much-needed support to navigate the tough decisions throughout their treatment journey.

    According to a report by WHO, 1 in every 10 Indians will develop cancer in their lifetime. There were as many as 1.16 million new cancer cases and 784,800 cancer deaths in 2018 alone. High mortality, combined with over 500 types of cancers, has generated a need for highly relevant information more than ever before.

    CURIA empowers patients and their families with individualized information about approved therapies, clinical trials, and medical experts. Built over the OncoCoin platform, CURIA offers services such as tailored information, second opinion, and the opportunity to participate in research programmes. The timely availability of this information at patient’s fingertips helps them navigate through tough decisions throughout their treatment journey.

    Speaking of this, Amit Ananpara, Innoplexus India Co-MD, said “Globally, 70% of cancer patients feel they do not get the information they need to make informed decisions. Specifically in India, limited knowledge of ongoing clinical trials leaves a gap in research involvement, stifling new insights. CURIA has successfully bridged such gaps in Europe. We look forward to helping cancer patients in India in their journey to cure.”

    Amit Ananpara and Gunjan Bhardwaj

    The tailored options in the app seek to answer three main questions which are often at the forefront of patients’ minds when they are diagnosed with cancer: ‘What are the treatment options available to me’, ‘What clinical trials could I participate in’, and ‘Who are the experts for my cancer type’. CURIA serves as a basis for patients to understand those options for their treatment journey, and to have more engaged discussions with their doctors about what’s right for them.

    Adding further, Gunjan Bhardwaj, Founder & CEO, Innoplexus, said, “Cancer is one of the most common non-communicable diseases in India today. What exacerbates the situation further is the fact that there is a clear lack of information on the condition. We aim to bridge this gap through CURIA and enable individuals with this condition to connect with other cancer patients and share information.”

    CURIA’s popular feature “Cancer Twin”, addresses patients’ need to connect with someone who really understands what they’re going through. The algorithm matches patients with the most similar other cancer profiles. They can share experiences through a private chat, anonymously. All conversations are encrypted through blockchain, bringing in the highest level of security to protect patient’s vital health information.

    CURIA’s India launch follows successful launches in Germany, Italy, Spain, Switzerland, and France. It is available on Android and iOS platforms.

    About Curia

    CURIA is a mobile application developed by OncoCoin AG, a Swiss-based wholly-owned subsidiary of Innoplexus AG. OncoCoin, using its patented AI and blockchain technologies, structures trillions of data points from published and unpublished data. The information is tailored by parameters such as demographics, cancer type, stage, possible mutations, to generate the most relevant insights for quick decision making. The insights are fully regulated by a human team of experts. Curia was founded in June 2020 by Innoplexus AG and sits in Eschborn, Germany. The app is currently available in Germany, India, Italy, France, Spain, and Switzerland.

  • Vaccination drive for 18+ has started at Dana Shivam Hospital Jaipur

    Jaipur (Rajasthan) [India], June 12: Dana Shivam Heart and Super-specialty hospital at Jaipur has started its vaccination drive for age over 18 at their hospital in Jaipur. As per the central govt guideline and instructions, hospital management is all prepared and set to deliver the vaccination doses.

    Dr. Sunil Garssa informed the media today, “We are fully prepared and started our vaccination drive as per the govt. guidelines and are ready with full hands to fight and put an end to this pandemic through all measures including vaccination drive.”

    “Vaccination is a key role player in this epidemic and if it is taken in time, it protects the user from the virus,” he added.

    Covaxin by Bharat Biotech, a proudly Indian-made vaccine, is ready for the users at the hospital premise in Vidhyadhar Nagar. The effects and results of Covaxin are good. Dr. Sunil told that this vaccine is very effective in preventing infection and if infection occurs it will be of mild state and side effects are also negligible and mild.

    As per Dr. Sunil, mild fever and tiredness may be experienced in some persons after vaccination, but hospital management has constructed a team of qualified personnel to properly follow up all the cases and assist them in fighting with these basic symptoms which may occur after the vaccination dose.  People don’t need to panic and this vaccination is a very important tool to fight this virus.

    “As a Doctor myself, I disagree with the rumors about the effectiveness and side effects of the vaccine. I get regular inquiries on daily basis about these rumors and we always emphasize educating such inquiries by telling them the advantages of vaccination,” he says.

    People still need to follow the basic Covid guideline of maintaining distance, eating healthy food, wearing a mask in public, regular hand wash and sanitization, whenever required.

    Dana Shivam Hospital is a Multi Super Specialty hospital based at Vidhyadhar Nagar, Jaipur, and operating for the last 6 years successfully. During the covid pandemic, the hospital’s management and staff are regularly fighting on the frontline and have saved thousands of lives so far. The hospital provides services in Cardiology, Cardiac Surgery, Vascular Surgery, Neurosurgery, Gastroenterology, Urology, Gastro related surgeries, plastic surgery, Gynaecology, Intensive Care Unit, Orthopedic, and ENT surgeries. With a bed capacity of 100 and a medical staff strength of 180, they are operational 24 X 7 and prepared for any medical emergency too.

    Dr. Sunil, who is the Director and Senior Consultant Cardiologist at Dana Shivam, has experience of successfully handling over 10,000 cases, particularly of acute heart attacks, with the helping hand of experienced Lab technicians and skilled Nursing staff. Multiple Trauma and Neurotrauma treatments are other expertise of Dana Shivam hospital.

    For his contribution and efforts, Dr. Sunil Garssa has also been awarded as ‘Business Leader in Field of Medicine’ for the year 2019 by Honorable Chief Minister Mr. Ashok Gehlot.

    Dana Shivam Hospital is completing 6 years of establishment and success this 17th July. The hospital team comprises medical experts like Dr. Shalini Tomar Garssa, Dr. Rajvir Singh Garssa, Dr. CP Suthar, Dr. Subhash Doot, Dr. Kamlesh Agarwal, Dr. Sanjay Goyal, Dr. Sunita Choudhary, Dr. Govind Dubey, Dr. Nitin Gupta, Dr. BK Chhabra, Dr. Shravan Choudhary, and Dr. Sushila Choudhary and the management is handled by SP Yadav, Narendra Singh Somra and Hemant Dangi.

  • Vaccination drive for 18+ has started at Dana Shivam Hospital Jaipur

    Jaipur (Rajasthan) [India], June 12: Dana Shivam Heart and Super-specialty hospital at Jaipur has started its vaccination drive for age over 18 at their hospital in Jaipur. As per the central govt guideline and instructions, hospital management is all prepared and set to deliver the vaccination doses.

    Dr. Sunil Garssa informed the media today, “We are fully prepared and started our vaccination drive as per the govt. guidelines and are ready with full hands to fight and put an end to this pandemic through all measures including vaccination drive.”

    “Vaccination is a key role player in this epidemic and if it is taken in time, it protects the user from the virus,” he added.

    Covaxin by Bharat Biotech, a proudly Indian-made vaccine, is ready for the users at the hospital premise in Vidhyadhar Nagar. The effects and results of Covaxin are good. Dr. Sunil told that this vaccine is very effective in preventing infection and if infection occurs it will be of mild state and side effects are also negligible and mild.

    As per Dr. Sunil, mild fever and tiredness may be experienced in some persons after vaccination, but hospital management has constructed a team of qualified personnel to properly follow up all the cases and assist them in fighting with these basic symptoms which may occur after the vaccination dose.  People don’t need to panic and this vaccination is a very important tool to fight this virus.

    “As a Doctor myself, I disagree with the rumors about the effectiveness and side effects of the vaccine. I get regular inquiries on daily basis about these rumors and we always emphasize educating such inquiries by telling them the advantages of vaccination,” he says.

    People still need to follow the basic Covid guideline of maintaining distance, eating healthy food, wearing a mask in public, regular hand wash and sanitization, whenever required.

    Dana Shivam Hospital is a Multi Super Specialty hospital based at Vidhyadhar Nagar, Jaipur, and operating for the last 6 years successfully. During the covid pandemic, the hospital’s management and staff are regularly fighting on the frontline and have saved thousands of lives so far. The hospital provides services in Cardiology, Cardiac Surgery, Vascular Surgery, Neurosurgery, Gastroenterology, Urology, Gastro related surgeries, plastic surgery, Gynaecology, Intensive Care Unit, Orthopedic, and ENT surgeries. With a bed capacity of 100 and a medical staff strength of 180, they are operational 24 X 7 and prepared for any medical emergency too.

    Dr. Sunil, who is the Director and Senior Consultant Cardiologist at Dana Shivam, has experience of successfully handling over 10,000 cases, particularly of acute heart attacks, with the helping hand of experienced Lab technicians and skilled Nursing staff. Multiple Trauma and Neurotrauma treatments are other expertise of Dana Shivam hospital.

    For his contribution and efforts, Dr. Sunil Garssa has also been awarded as ‘Business Leader in Field of Medicine’ for the year 2019 by Honorable Chief Minister Mr. Ashok Gehlot.

    Dana Shivam Hospital is completing 6 years of establishment and success this 17th July. The hospital team comprises medical experts like Dr. Shalini Tomar Garssa, Dr. Rajvir Singh Garssa, Dr. CP Suthar, Dr. Subhash Doot, Dr. Kamlesh Agarwal, Dr. Sanjay Goyal, Dr. Sunita Choudhary, Dr. Govind Dubey, Dr. Nitin Gupta, Dr. BK Chhabra, Dr. Shravan Choudhary, and Dr. Sushila Choudhary and the management is handled by SP Yadav, Narendra Singh Somra and Hemant Dangi.

  • Medical Termination of Pregnancy in India: Evidence-Based Learnings for Policymakers

    Susheela Singh, Rubina Hussain, Chander Shekhar, Rajib Acharya, Melissa Stillman, Ann M Moore

     

    New Delhi [India], June 9: Abortion in India continues to face high levels of stigma– this stigma pushes women seeking abortion away from legal services; curtails dissemination of information on abortion, and affects the delivery of essential services in the public health system. Consequently, millions of women prefer not to go to public health facilities for abortion services. It is estimated that 78% of the 15.6 million abortions that take place each year in India occur in non-facility settings, mainly through medical abortion pills.

    Newly published evidence (Incidence of Treatment for Postabortion Complications in India, 2015) in BMJ Global Health further suggests that in 2015, 5.2 million women in India received treatment for induced abortion complications, a treatment rate of 15.7 per 1000 women aged 15–49; comparable to countries where abortion law is highly restrictive, and unsafe abortion is likely to be prevalent. Notably, many of the patients who were treated for postabortion complications resulting from the use of medical abortion pills may not have needed treatment to complete their abortion – if they had been provided accurate information on how the method works, what to expect after taking the pills, and how to recognize a complication.

    On March 16th, 2021, the Indian Parliament passed amendments to the Medical Termination of Pregnancy (MTP) Bill 2020; while on the one hand the Bill is being applauded for removing some recurring barriers for women seeking abortions; it is also being criticized for not empowering women with complete choice. However, we should not underestimate the opportunities this policy reform brings: It has the potential to improve the experiences of millions of women who terminate unintended pregnancies in India each year.

    Firstly, the MTP Act and its Regulations and operational guidelines currently only permit obstetrician gynaecologists and MBBS doctors who have been trained and registered to provide abortion in approved facilities.  Therefore, policymakers need to consider expanding the provider base for legal abortion services. Registered providers in unapproved facilities may provide medical abortion; however, they must have referral linkages to approved facilities. The training requirements as laid out in the abortion law are rigorous and do not distinguish between surgical and medical methods of abortion. Given this situation, the government could increase access to safe abortion services by permitting and providing simplified training to a larger number of providers, who would then be certified to provide medical abortion only. This will not only significantly increase the options for women seeking abortion services but also leverage the potential of medical abortion technology. The paper also recommends that to ensure that women seeking abortions are well-supported and provided credible information, including on referral facilities, policies should extensively cover community health intermediaries and equip them with adequate information to direct and guide women looking to terminate an unwanted pregnancy.

    Secondly, there is a need to improve the experience of women seeking treatment for post-abortion complications in public facilities. In the study – Incidence of Treatment for Postabortion Complications in India, 2015- conducted in six Indian states—Assam, Bihar, Gujarat, Madhya Pradesh, Tamil Nadu, and Uttar Pradesh, respondents estimated that a variable but high proportion of all women receiving postabortion care were admitted with incomplete abortion from use of medical abortion; Prolonged or abnormal bleeding and incomplete abortion resulting from use of methods other than medical abortion were also common complications. However, it should be noted that the clinical efficacy of medical abortion in the early gestation period is95%–98% when the method is used correctly and drugs are of high quality, and at a minimum 2%–5% of all users of medical abortion would have incomplete abortions and may need medical treatment.

    Since most medical abortion users in India obtain the method outside of the formal health system and the method they are using is highly effective, the paper points to the possibility for patients to experience an incomplete abortion or other complications as a result of the medication being administered incorrectly or the medication is being compromised. Nevertheless, this points to the important recommendation that to improve women’s experience of using medical abortion, all women who use medical abortion (and especially those who obtain it outside of facilities) must receive accurate information and good quality medical abortion supplies. However, for those who still approach facilities for treatment of post-abortion complications following medical abortion, there is a need to address a range of issues such as inadequate privacy and confidentiality, provider biases, and cost barriers.

    Lastly, it is imperative that women have access to accurate information on medical abortion regardless of the source of care preferences. One way to do this, as the paper recommends, would be to improve access to information via inserts in medical abortion packets to help facilitate women’s ability to use the method correctly, know what to expect and when to seek care. There is also a need for innovative approaches for public dissemination of information about the correct usage of the method by means that reach more women.

    Medical abortion is a safe and effective technology that has had a major impact in opening up access to safe abortion for women in India. It is imperative that we leverage it for expanding legal providers in the formal health system while also making accurate information available to women on the usage of the method.

    This article is based on a research paper:

    Singh S, Hussain R, Shekhar C, et al. Incidence of treatment for postabortion complications in India, 2015. BMJ Global Health 2020

    http://dx.doi.org/10.1136/bmjgh-2020-002372